Review ArticleReview
Open Access

Clinical Impact of Nutrition and Inflammation Assessment Tools in Gastric Cancer Treatment

TORU AOYAMA, KENTARO HARA, KEISUKE KAZAMA and YUKIO MAEZAWA
Anticancer Research November 2022, 42 (11) 5167-5180; DOI: https://doi.org/10.21873/anticanres.16023

Abstract

The standard treatment for gastric cancer is surgical resection and perioperative adjuvant treatment. Multidisciplinary treatment for gastric cancer leads to nutritional and inflammatory changes. Nutritional and inflammatory changes during multidisciplinary treatment can lead to poor physical activity, severe toxicity in patients receiving chemotherapy or radiation therapy, and poor oncological outcomes. Evaluation of the perioperative nutritional and inflammatory status during treatment is necessary in order to utilize and optimize multidisciplinary therapy for gastric cancer. If physicians were able to detect the perioperative nutritional and inflammatory status before and during gastric cancer treatment, they would be able to select the optimal treatment and perioperative nutritional treatment. Recently, various types of nutrition and inflammation assessment tools were developed and reported for gastric cancer. These nutrition and inflammation assessment tools have some clinical advantages, such as ease of implementation, perioperative accessibility, and low cost. On the other hand, each tool has its own clinical characteristics, which must be understood before using it in the clinical practice. This review summarizes the background, current status, and future perspectives on the application of nutrition and inflammation assessment tools in gastric cancer treatment.

Key Words:

An estimated 19.3 million new cancer cases and 10.0 million cancer deaths occurred worldwide in 2020 (1, 2). Among them, gastric cancer is one of the most frequent types of cancer. Curative resection and perioperative adjuvant treatment is the standard treatment for gastric cancer (3-5). Although the prognosis of patients with gastric cancer is gradually improving, more than half of patients develop recurrent disease, even after curative treatment (6, 7). Thus, in order to improve the prognosis of gastric cancer, it is necessary to identify useful prognostic factors.

Thus far, the perioperative nutritional status and the inflammatory status have been shown to affect short-term oncological outcomes, including postoperative surgical complications, continuation of adjuvant treatment, and adverse events of adjuvant treatment (8-12). In addition, the perioperative nutritional status and inflammatory status affect the long-term oncological outcomes (13, 14). The evaluation of the perioperative nutritional status and the inflammatory status during treatment is necessary for utilizing and optimizing multidisciplinary therapy for gastric cancer. If physicians were able to detect the perioperative nutritional status and inflammatory status before and during gastric cancer treatment, they would be select optimal treatment and perioperative nutritional treatment. Recently, various types of nutrition and inflammation assessment tools for patients with gastric cancer have been developed and reported. The perioperative nutritional assessment of gastric cancer has been based on changes in body composition, blood biochemistry, or a combination of both. These nutrition and inflammation assessment tools have some clinical advantages, including ease of implementation, perioperative accessibility, and low cost. On the other hand, each tool has its own clinical characteristics, therefore it is necessary to understand the characteristics of each nutrition and inflammation assessment tool before using it in clinical practice.

This review summarizes the background, current status, and future perspectives of nutrition and inflammation assessment tools for gastric cancer treatment.

Clinical Use of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in Gastric Cancer Treatment

The Glasgow Prognostic Score (GPS) was first reported by Forrest and McMillan (15). The GPS is determined from the serum C-reactive protein level (CRP) and serum albumin level. The CRP level reflects the systemic inflammation status and the albumin level reflect the nutritional status. Therefore, the GPS can assess both the inflammatory and nutritional status associated with malignancy. The GPS is determined as follows: Cases with both elevated CRP (>10 mg/l) and low albumin (<35 g/l) are scored as 2; cases with only one of these biochemical abnormalities are scored as 1; and cases with neither of these abnormalities are scored as 0. After further investigation, the GPS was modified. The mGPS is scored as follows: Cases with both elevated CRP (>10 mg/l) and low albumin (<35 g/l) are scored as 2; cases with elevated CRP are scored as 1; and cases with neither elevated CRP nor low albumin are scored as 0. A total of 17 studies have evaluated the clinical impact of the GPS/mGPS in gastric cancer. Table I summarizes each study (16-32). In previous studies, the cut-off value of the GPS/mGPS was 1 or 2. Among them, 10 studies evaluated resectable gastric cancer and seven evaluated unresectable gastric cancer. In both the resectable and unresectable settings, a high GPS/mGPS (more than 1 or 2) was associated with a poor prognosis. The hazard ratio (HR) of GPS/mGPS for overall survival (OS) was 1.042-5.07 in the resectable setting and 1.621-5.89 in the unresectable setting. In addition, two studies showed that a high GPS/mGPS was associated with the occurrence of postoperative surgical complications. Accordingly, GPS and mGPS have clinical impact in relation to both the short- and long-term oncological outcomes in gastric cancer.

View this table:
Table I.

Literature investigating the utility of the Glasgow Prognostic Score (GPS)/modified Glasgow Prognostic Score (mGPS) in patients with gastric cancer.

The C-Reactive Protein-to Albumin-Ratio in Gastric Cancer Treatment

The C-reactive protein to albumin ratio (CRP/Alb) is derived from laboratory tests. The CRP/Alb is determined by dividing the serum CRP level by the albumin level. CRP is an acute-phase response protein synthesized by liver cells and is one of the most sensitive indicators of inflammation. Albumin is synthesized by the liver and is the main component of human serum total protein. Albumin plays an important role in maintaining blood colloid osmotic pressure, transporting metabolites, and reflects the nutritional status. Therefore, the CRP/Alb ratio reflects both the inflammation status and the nutrition status. Thus far, 11 studies have evaluated the clinical impact of CRP/Alb in gastric cancer. Table II summarizes each study (33-43). Among them, nine studies evaluated CRP/Alb as a prognostic factor, while two studies evaluated it as a predictive factor for postoperative surgical complications. The cut-off CRP/Alb value was reported to range from 0.025 to 0.3778 as a prognostic factor in the previous studies. In the evaluation as a prognostic factor, a high CRP/Alb value was associated with a poor prognosis. The hazard ratio (HR) of the CRP/Alb value for OS was 1.626-2.844. In addition, two studies showed that a high CRP/Alb value was associated with the occurrence of postoperative surgical complications. Accordingly, the CRP/Alb value is considered to have a clinical impact on both the short- and long-term oncological outcomes. Further studies are needed to clarify whether CRP/Alb is an optimal tool for unresectable gastric cancer. In other malignancies, recent studies showed that the CRP/Alb ratio is a promising marker for selecting patients who are eligible for chemotherapy or as a predictor of adverse events of chemotherapy. These issues need to be clarified in gastric cancer.

View this table:
Table II.

Literature investigating the utility of the C-reactive protein-to albumin-ratio in patients with gastric cancer.

The Neutrophil-to-Lymphocyte Ratio in Gastric Cancer Treatment

The neutrophil-lymphocyte ratio (NLR) was first recognized for its association with systemic inflammation in the critically ill, and meta-analyses on the association between an elevated NLR and a poor prognosis have been reported for various malignancies. The NLR is determined by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLR can easily be calculated from parameters that are obtained in routine blood cell counts. The close association between inflammation and cancer progression hints at the potential application of elevated tumor-associated neutrophils, or neutrophils that infiltrate tumors, as a prognostic biomarker. Thus far, 63 studies have evaluated the clinical impact of NLR in gastric cancer. Table III summarizes each study (18, 44-97). Among them, 60 studies evaluated the NLR as a prognostic factor, three evaluated the NLR as a predictive factor for postoperative surgical complications. Among 60 studies that evaluated the NLR as a prognostic factor, 34 evaluated its role in resectable gastric cancer and 26 studies evaluated unresectable gastric cancer. In both the resectable and unresectable settings, a high NLR was associated with a poor prognosis. The HR of NLR for OS was 1.1-14.621 in the resectable setting and 1.116-11.41 in the unresectable setting. The cut-off value of the NLR was reported to be 1.7-5 in the resectable setting and 1.5-5 in the unresectable setting. In addition, three studies showed that a high NLR was associated with the occurrence of postoperative surgical complications. Accordingly, the NLR had clinical impact in both short- and long-term oncological outcomes in resectable and unresectable settings. Recently, changes of the NLR during treatment have been reported to be associated with gastric cancer survival. Further studies are needed to clarify this issue.

View this table:
Table III.

Literature investigating the utility of the neutrophil-to-lymphocyte ratio in patients with gastric cancer.

The Platelet-to-Lymphocyte Ratio in Gastric Cancer Treatment

Recently, the platelet-to-lymphocyte ratio (PLR) was developed and reported as a promising prognostic factor for gastrointestinal malignancies. The PLR is particularly promising as it can potentially provide insight into both cancer-related inflammation and cancer-related thrombotic/hemostatic mechanisms in various malignancies. Five studies have evaluated the clinical impact of the PLR in gastric cancer. Table IV summarizes each study (39, 48, 98-100). Among them, four studies evaluated the PLR as a prognostic factor, while one study evaluated the PLR as a predictive factor for postoperative surgical complications. The cut-off value of the PLR as a prognostic factor was reported to be 159-191 in the previous studies. In evaluation as a prognostic factor, a high PLR was associated with a poor prognosis. The HR of the PLR for OS was 1.552-2.47. Although almost 30 studies have assessed the prognostic value of the PLR in gastric cancer, limited studies showed that the PLR had a significant impact for OS in gastric cancer. Therefore, further studies are needed to clarify the clinical impact of the PLR in gastric cancer treatment.

View this table:
Table IV.

Literature investigating the utility of the platelet-to-lymphocyte ratio in patients with gastric cancer.

The Prognostic Nutritional Index in Gastric Cancer Treatment

The prognostic nutritional index (PNI) is a novel method to assess the immune and nutritional status based on the serum lymphocyte count and albumin level. Twenty-six studies have evaluated the clinical impact of the PNI in gastric cancer. Table V summarizes each study (77, 101-124). Among the 26 studies that evaluated the PNI as a prognostic factor, 24 evaluated resectable gastric cancer and two evaluated unresectable gastric cancer. In both the resectable and unresectable settings, a high PNI was associated with a poor prognosis. The HR of the PNI for OS was 1.287-12.933 in the resectable setting. The cut-off value of the PNI was reported to be 41-50 in the resectable setting and 40 in the unresectable setting. Recent studies have reported that the immune status and nutritional status affect the continuation of chemotherapy and the occurrence of adverse events of chemotherapy. Therefore, the PNI may have some clinical impact in patients with unresectable gastric cancer who receive chemotherapy. Further studies are needed to clarify this issue.

View this table:
Table V.

Literature investigating the utility of the Prognostic Nutritional Index in patients with gastric cancer.

Controlling Nutritional Status in Gastric Cancer Treatment

The controlling nutritional status (CONUT) score was developed as an accessible nutritional screening tool for evaluating a patient’s nutritional status. The CONUT score is calculated from the serum albumin level, the total cholesterol level, and the total lymphocyte count. The clinical impact of the CONUT score on the outcomes of gastric cancer was first reported in 2018. Twenty-six studies have evaluated the clinical impact of the PNI in gastric cancer. Table VI summarizes each study (125-137). Among 11 studies that evaluated the CONUT score as a prognostic factor, 10 evaluated patients with resectable gastric cancer and one evaluated those with unresectable gastric cancer. In both settings, a high CONUT score was associated with a poor prognosis. The HR of the CONUT score for OS was 1.553-3.707 in the resectable setting. The cut-off value of the CONUT score was reported to be 0-5. In addition, four studies evaluated the CONUT score as a predictive factor for postoperative surgical complications. These studies showed that a high CONUT score was associated with postoperative surgical complications.

View this table:
Table VI.

Literature investigating the utility of the Controlling Nutritional Status in patients with gastric cancer.

The Albumin-to-Globulin Ratio and the Lymphocyte-to-C-Reactive Protein Ratio in Gastric Cancer Treatment

Recently, the clinical utilities of albumin and globulin as tumor prognostic markers have aroused great interest. The albumin-to-globulin ratio (AGR), which is calculated as AGR=albumin/(total protein−albumin) has been considered a possible effective combination of two prognostic indicators. In addition, the lymphocyte-to-C-reactive protein ratio (LCR) is a particularly promising marker of systemic inflammation in the perioperative period. Table VII (112, 138) and Table VIII (139-141) showed the clinical impacts of the AGR and LCR in gastric cancer treatment. However, limited studies have shown its significance as a prognostic factor in gastric cancer treatment. Additional studies are needed to clarify the clinical impact of the AGR and LCR in gastric cancer treatment.

View this table:
Table VII.

Literature investigating the utility of the albumin-to-globulin ratio in patients with gastric cancer.

View this table:
Table VIII.

Literature investigating the utility of the lymphocyte-to-C-reactive protein ratio in patients with gastric cancer.

Future Prospects for Nutrition and Inflammation Assessment Tools for Gastric Cancer Treatment

Thus far, various nutrition and inflammation assessment tools have been applied in gastric cancer treatment. To utilize the nutrition and inflammation assessment tools in gastric cancer treatment, the following points should be clarified. Firstly, it is necessary to set the optimal cut-off value for each nutrition and inflammation assessment tool. In the previous studies, patient background factors and treatment methods were heterogeneous. In addition, the sample sizes of the previous studies were relatively small and the studies were retrospective in nature. Therefore, these differences may have affected the cut-off values used for each tool. In addition, the timing of the application of these tools is also unclear. Previous studies assessed each tool at the preoperative, postoperative, and pretreatment of chemotherapy. It is necessary to establish the optimal timing for assessment by these tools. Secondly, the mechanisms through which nutrition and inflammation affect the prognosis of gastric cancer are unclear. Recently, the nutrition and inflammation status has been reported to affect postoperative surgical complications, the introduction of chemotherapy, and adverse events of chemotherapy. Previous studies demonstrated that postoperative surgical complications and the management of chemotherapy affect survival of patients with gastric cancer. However, the precise mechanism through which the nutritional and inflammatory status – as assessed by these tools – influences gastric cancer prognosis is unclear. Thirdly, it is unclear whether nutrition and inflammation assessment using these tools will become promising aids for defining treatment approaches targeting nutrition/inflammation in gastric cancer. Recent studies have focused on introducing perioperative oral nutritional treatment for patients with gastrointestinal cancer. The clinical relationship between changes in the nutritional and inflammatory status and perioperative oral nutritional treatment still needs to be clarified.

Conclusion

The nutritional and inflammatory status—as assessed by nutrition and inflammation assessment tools—may have some clinical influence on both the short- and long-term oncological outcomes in patients with gastric cancer. However, the optimal cut-off values for each tool have not been established and the mechanism through which these parameters influence prognosis is unclear. To optimize the nutrition and inflammation assessment tools for gastric cancer, it is necessary to clarify these points in further studies.

Acknowledgements

This work was supported by JSPS KAKENHI Grant Number 21K08688.

Footnotes

  • ↵* These Authors contributed equally to this article.

  • Authors’ Contributions

    TA and KH made substantial contributions to the concept and design. TA, YM, KH, and KK made substantial contributions to the acquisition of data and the analysis and interpretation of the data. TA and YM were involved in drafting the article or revising it critically for important intellectual content. TA, and KH gave their final approval of the version to be published.

  • Conflicts of interest

    None.

  • Received September 6, 2022.
  • Revision received September 23, 2022.
  • Accepted September 28, 2022.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Sung H,
    2. Ferlay J,
    3. Siegel RL,
    4. Laversanne M,
    5. Soerjomataram I,
    6. Jemal A and
    7. Bray F
    : Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3): 209-249, 2021. PMID: 33538338. DOI: 10.3322/caac.21660
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA and
    6. Jemal A
    : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
    OpenUrlCrossRefPubMed
  3. ↵
    1. Japanese Gastric Cancer Association
    : Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24(1): 1-21, 2021. PMID: 32060757. DOI: 10.1007/s10120-020-01042-y
    OpenUrlCrossRefPubMed
    1. National Comprehensive Cancer Network
    : NCCN Clinical Practice Guidelines in Oncology, 2018. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf [Last accessed on September 28, 2022]
  5. ↵
    1. Smyth EC,
    2. Verheij M,
    3. Allum W,
    4. Cunningham D,
    5. Cervantes A,
    6. Arnold D and ESMO Guidelines Committee
    : Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5): v38-v49, 2016. PMID: 27664260. DOI: 10.1093/annonc/mdw350
    OpenUrlCrossRefPubMed
  6. ↵
    1. Muro K,
    2. Van Cutsem E,
    3. Narita Y,
    4. Pentheroudakis G,
    5. Baba E,
    6. Li J,
    7. Ryu MH,
    8. Zamaniah WIW,
    9. Yong WP,
    10. Yeh KH,
    11. Kato K,
    12. Lu Z,
    13. Cho BC,
    14. Nor IM,
    15. Ng M,
    16. Chen LT,
    17. Nakajima TE,
    18. Shitara K,
    19. Kawakami H,
    20. Tsushima T,
    21. Yoshino T,
    22. Lordick F,
    23. Martinelli E,
    24. Smyth EC,
    25. Arnold D,
    26. Minami H,
    27. Tabernero J and
    28. Douillard JY
    : Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 30(1): 19-33, 2019. PMID: 30475956. DOI: 10.1093/annonc/mdy502
    OpenUrlCrossRefPubMed
  7. ↵
    1. Pentheroudakis G and ESMO Guidelines Committee
    : Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. Ann Oncol 30(8): 1395-1397, 2019. PMID: 31168599. DOI: 10.1093/annonc/mdz180
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ju M,
    2. Aoyama T,
    3. Komori K,
    4. Tamagawa H,
    5. Tamagawa A,
    6. Maezawa Y,
    7. Morita J,
    8. Onodera A,
    9. Endo K,
    10. Hashimoto I,
    11. Kano K,
    12. Hara K,
    13. Cho H,
    14. Nakazono M,
    15. Segami K,
    16. Ishiguro T,
    17. Onuma S,
    18. Oshima T,
    19. Yukawa N and
    20. Rino Y
    : The albumin-bilirubin score is a prognostic factor for gastric cancer patients who receive curative treatment. Anticancer Res 42(8): 3929-3935, 2022. PMID: 35896262. DOI: 10.21873/anticanres.15887
    OpenUrlAbstract/FREE Full Text
    1. Aoyama T,
    2. Ju M,
    3. Komori K,
    4. Tamagawa H,
    5. Tamagawa A,
    6. Onodera A,
    7. Morita J,
    8. Hashimoto I,
    9. Ishiguro T,
    10. Endo K,
    11. Cho H,
    12. Onuma S,
    13. Fukuda M,
    14. Oshima T,
    15. Yukawa N and
    16. Rino Y
    : The platelet-to-lymphocyte ratio is an independent prognostic factor for patients with esophageal cancer who receive curative treatment. In Vivo 36(4): 1916-1922, 2022. PMID: 35738628. DOI: 10.21873/invivo.12912
    OpenUrlAbstract/FREE Full Text
    1. Aoyama T,
    2. Ju M,
    3. Komori K,
    4. Tamagawa H,
    5. Tamagawa A,
    6. Morita J,
    7. Hashimoto I,
    8. Ishiguro T,
    9. Onodera A,
    10. Cho H,
    11. Endo K,
    12. Onuma S,
    13. Kano K,
    14. Hara K,
    15. Fukuda M,
    16. Oshima T,
    17. Yukawa N and
    18. Rino Y
    : Clinical impact of platelet-to-albumin ratio on esophageal cancer patients who receive curative treatment. In Vivo 36(4): 1896-1902, 2022. PMID: 35738593. DOI: 10.21873/invivo.12909
    OpenUrlAbstract/FREE Full Text
    1. Aoyama T,
    2. Ju M,
    3. Komori K,
    4. Tamagawa H,
    5. Tamagawa A,
    6. Maezawa Y,
    7. Hashimoto I,
    8. Kano K,
    9. Hara K,
    10. Cho H,
    11. Segami K,
    12. Machida D,
    13. Nakazono M,
    14. Oshima T,
    15. Yukawa N and
    16. Rino Y
    : The systemic inflammation score is an independent prognostic factor for esophageal cancer patients who receive curative treatment. Anticancer Res 42(5): 2711-2717, 2022. PMID: 35489731. DOI: 10.21873/anticanres.15749
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Aoyama T,
    2. Ju M,
    3. Machida D,
    4. Komori K,
    5. Tamagawa H,
    6. Tamagawa A,
    7. Maezawa Y,
    8. Kano K,
    9. Hara K,
    10. Segami K,
    11. Hashimoto I,
    12. Nagasawa S,
    13. Nakazono M,
    14. Oshima T,
    15. Yukawa N and
    16. Rino Y
    : Clinical impact of preoperative albumin-bilirubin status in esophageal cancer patients who receive curative treatment. In Vivo 36(3): 1424-1431, 2022. PMID: 35478112. DOI: 10.21873/invivo.12847
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Aoyama T
    : Perioperative body composition changes in the multimodal treatment of gastrointestinal cancer. Surg Today 50(3): 217-222, 2020. PMID: 31028458. DOI: 10.1007/s00595-019-01815-8
    OpenUrlCrossRefPubMed
  14. ↵
    1. Yoon SL,
    2. Grundmann O,
    3. Williams JJ,
    4. Gordan L and
    5. George TJ Jr.
    : Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study. Cancer Med 7(8): 3695-3703, 2018. PMID: 29971962. DOI: 10.1002/cam4.1665
    OpenUrlCrossRefPubMed
  15. ↵
    1. Scott HR,
    2. McMillan DC,
    3. Forrest LM,
    4. Brown DJ,
    5. McArdle CS and
    6. Milroy R
    : The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3): 264-267, 2002. PMID: 12177792. DOI: 10.1038/sj.bjc.6600466
    OpenUrlCrossRefPubMed
  16. ↵
    1. Nozoe T,
    2. Iguchi T,
    3. Egashira A,
    4. Adachi E,
    5. Matsukuma A and
    6. Ezaki T
    : Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg 201(2): 186-191, 2011. PMID: 20832047. DOI: 10.1016/j.amjsurg.2010.01.030
    OpenUrlCrossRefPubMed
    1. Kubota T,
    2. Hiki N,
    3. Nunobe S,
    4. Kumagai K,
    5. Aikou S,
    6. Watanabe R,
    7. Sano T and
    8. Yamaguchi T
    : Significance of the inflammation-based Glasgow prognostic score for short- and long-term outcomes after curative resection of gastric cancer. J Gastrointest Surg 16(11): 2037-2044, 2012. PMID: 23007284. DOI: 10.1007/s11605-012-2036-x
    OpenUrlCrossRefPubMed
  18. ↵
    1. Jeong JH,
    2. Lim SM,
    3. Yun JY,
    4. Rhee GW,
    5. Lim JY,
    6. Cho JY and
    7. Kim YR
    : Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology 83(5): 292-299, 2012. PMID: 22964877. DOI: 10.1159/000342376
    OpenUrlCrossRefPubMed
    1. Kunisaki C,
    2. Takahashi M,
    3. Ono HA,
    4. Oshima T,
    5. Takagawa R,
    6. Kimura J,
    7. Kosaka T,
    8. Makino H,
    9. Akiyama H and
    10. Endo I
    : Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology 83(4): 183-191, 2012. PMID: 22890015. DOI: 10.1159/000341346
    OpenUrlCrossRefPubMed
    1. Hwang JE,
    2. Kim HN,
    3. Kim DE,
    4. Choi HJ,
    5. Jung SH,
    6. Shim HJ,
    7. Bae WK,
    8. Hwang EC,
    9. Cho SH and
    10. Chung IJ
    : Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 11: 489, 2011. PMID: 22103888. DOI: 10.1186/1471-2407-11-489
    OpenUrlCrossRefPubMed
    1. Jiang X,
    2. Hiki N,
    3. Nunobe S,
    4. Kumagai K,
    5. Kubota T,
    6. Aikou S,
    7. Sano T and
    8. Yamaguchi T
    : Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer 107(2): 275-279, 2012. PMID: 22713657. DOI: 10.1038/bjc.2012.262
    OpenUrlCrossRefPubMed
    1. Dutta S,
    2. Crumley AB,
    3. Fullarton GM,
    4. Horgan PG and
    5. McMillan DC
    : Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg 204(3): 294-299, 2012. PMID: 22444831. DOI: 10.1016/j.amjsurg.2011.10.015
    OpenUrlCrossRefPubMed
    1. Mimatsu K,
    2. Oida T,
    3. Fukino N,
    4. Kano H,
    5. Kawasaki A,
    6. Kida K,
    7. Kuboi Y and
    8. Amano S
    : Glasgow prognostic score is a useful predictive factor of outcome after palliative gastrectomy for stage IV gastric cancer. Anticancer Res 34(6): 3131-3136, 2014. PMID: 24922683.
    OpenUrlAbstract/FREE Full Text
    1. Li QQ,
    2. Lu ZH,
    3. Yang L,
    4. Lu M,
    5. Zhang XT,
    6. Li J,
    7. Zhou J,
    8. Wang XC,
    9. Gong JF,
    10. Gao J,
    11. Li J,
    12. Li Y and
    13. Shen L
    : Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev 15(2): 945-950, 2014. PMID: 24568523. DOI: 10.7314/apjcp.2014.15.2.945
    OpenUrlCrossRefPubMed
    1. Ishizuka M,
    2. Oyama Y,
    3. Abe A,
    4. Tago K,
    5. Tanaka G and
    6. Kubota K
    : Clinical significance of an inflammation-based prognostic system for gastric cancer patients with a preoperative normal serum level of carcinoembryonic antigen. Anticancer Res 34(12): 7219-7226, 2014. PMID: 25503152.
    OpenUrlAbstract/FREE Full Text
    1. Melling N,
    2. Grüning A,
    3. Tachezy M,
    4. Nentwich M,
    5. Reeh M,
    6. Uzunoglu FG,
    7. Vashist YK,
    8. Izbicki JR and
    9. Bogoevski D
    : Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment. Surgery 159(6): 1548-1556, 2016. PMID: 26899471. DOI: 10.1016/j.surg.2016.01.018
    OpenUrlCrossRefPubMed
    1. Namikawa T,
    2. Yokota K,
    3. Tanioka N,
    4. Fukudome I,
    5. Iwabu J,
    6. Munekage M,
    7. Uemura S,
    8. Maeda H,
    9. Kitagawa H,
    10. Kobayashi M and
    11. Hanazaki K
    : Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today 50(11): 1486-1495, 2020. PMID: 32542414. DOI: 10.1007/s00595-020-02048-w
    OpenUrlCrossRefPubMed
    1. Hsueh SW,
    2. Liu KH,
    3. Hung CY,
    4. Kuo YC,
    5. Tsai CY,
    6. Hsu JT,
    7. Hung YS,
    8. Tsang NM and
    9. Chou WC
    : Significance of the Glasgow Prognostic Score in predicting the postoperative outcome of patients with stage III gastric cancer. J Clin Med 8(9): 1448, 2019. PMID: 31547247. DOI: 10.3390/jcm8091448
    OpenUrlCrossRefPubMed
    1. Kurosaki T,
    2. Kawakami H,
    3. Mitani S,
    4. Kawabata R,
    5. Takahama T,
    6. Nonagase Y,
    7. Fumita S,
    8. Ozaki T,
    9. Chiba Y,
    10. Tamura T and
    11. Nakagawa K
    : Glasgow Prognostic Score (GPS) and tumor response as biomarkers of nivolumab monotherapy in third- or later-line setting for advanced gastric cancer. In Vivo 34(4): 1921-1929, 2020. PMID: 32606164. DOI: 10.21873/invivo.11989
    OpenUrlAbstract/FREE Full Text
    1. Tokuyama N,
    2. Takegawa N,
    3. Nishikawa M,
    4. Sakai A,
    5. Mimura T,
    6. Kushida S,
    7. Tsumura H,
    8. Yamamoto Y,
    9. Miki I and
    10. Tsuda M
    : Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS One 16(2): e0247645, 2021. PMID: 33635904. DOI: 10.1371/journal.pone.0247645
    OpenUrlCrossRefPubMed
    1. Shimoda Y,
    2. Fujikawa H,
    3. Komori K,
    4. Watanabe H,
    5. Takahashi K,
    6. Kano K,
    7. Yamada T,
    8. Shiozawa M,
    9. Morinaga S,
    10. Katsumata K,
    11. Tsuchida A,
    12. Ogata T and
    13. Oshima T
    : The Glasgow Prognostic Score before curative resection may predict postoperative complications in patients with gastric cancer. J Gastrointest Cancer, 2021. PMID: 34519976. DOI: 10.1007/s12029-021-00689-9
    OpenUrlCrossRefPubMed
  32. ↵
    1. Zhang S,
    2. Li JZ,
    3. Du T,
    4. Li HQ,
    5. Hu RH,
    6. Ma CY,
    7. Cui XM,
    8. Song C and
    9. Jiang XH
    : The modified Glasgow Prognostic Score predicts survival in gastric cancer patients with normal CEA and CA19-9. Can J Gastroenterol Hepatol 2022: 3953004, 2022. PMID: 35734015. DOI: 10.1155/2022/3953004
    OpenUrlCrossRefPubMed
  33. ↵
    1. Liu X,
    2. Sun X,
    3. Liu J,
    4. Kong P,
    5. Chen S,
    6. Zhan Y and
    7. Xu D
    : Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol 8(4): 339-345, 2015. PMID: 26310380. DOI: 10.1016/j.tranon.2015.06.006
    OpenUrlCrossRefPubMed
    1. Toiyama Y,
    2. Shimura T,
    3. Yasuda H,
    4. Fujikawa H,
    5. Okita Y,
    6. Kobayashi M,
    7. Ohi M,
    8. Yoshiyama S,
    9. Hiro J,
    10. Araki T,
    11. Inoue Y,
    12. Mohri Y and
    13. Kusunoki M
    : Clinical burden of C-reactive protein/albumin ratio before curative surgery for patients with gastric cancer. Anticancer Res 36(12): 6491-6498, 2016. PMID: 27919972. DOI: 10.21873/anticanres.11248
    OpenUrlAbstract/FREE Full Text
    1. Mao M,
    2. Wei X,
    3. Sheng H,
    4. Chi P,
    5. Liu Y,
    6. Huang X,
    7. Xiang Y,
    8. Zhu Q,
    9. Xing S and
    10. Liu W
    : C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. Oncol Lett 14(6): 7417-7424, 2017. PMID: 29344182. DOI: 10.3892/ol.2017.7179
    OpenUrlCrossRefPubMed
    1. Saito H,
    2. Kono Y,
    3. Murakami Y,
    4. Shishido Y,
    5. Kuroda H,
    6. Matsunaga T,
    7. Fukumoto Y,
    8. Osaki T,
    9. Ashida K and
    10. Fujiwara Y
    : Prognostic significance of the preoperative ratio of C-reactive protein to albumin and neutrophil-lymphocyte ratio in gastric cancer patients. World J Surg 42(6): 1819-1825, 2018. PMID: 29270656. DOI: 10.1007/s00268-017-4400-1
    OpenUrlCrossRefPubMed
    1. Xu BB,
    2. Lu J,
    3. Zheng ZF,
    4. Xie JW,
    5. Wang JB,
    6. Lin JX,
    7. Chen QY,
    8. Cao LL,
    9. Lin M,
    10. Tu RH,
    11. Huang ZN,
    12. Lin JL,
    13. Zheng CH,
    14. Huang CM and
    15. Li P
    : The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data. Gastric Cancer 22(5): 1016-1028, 2019. PMID: 30739259. DOI: 10.1007/s10120-019-00936-w
    OpenUrlCrossRefPubMed
    1. Kudou K,
    2. Saeki H,
    3. Nakashima Y,
    4. Kamori T,
    5. Kawazoe T,
    6. Haruta Y,
    7. Fujimoto Y,
    8. Matsuoka H,
    9. Sasaki S,
    10. Jogo T,
    11. Hirose K,
    12. Hu Q,
    13. Tsuda Y,
    14. Kimura K,
    15. Ando K,
    16. Oki E,
    17. Ikeda T and
    18. Maehara Y
    : C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol 34(2): 355-363, 2019. PMID: 30119141. DOI: 10.1111/jgh.14442
    OpenUrlCrossRefPubMed
  39. ↵
    1. Toyokawa T,
    2. Muguruma K,
    3. Yoshii M,
    4. Tamura T,
    5. Sakurai K,
    6. Kubo N,
    7. Tanaka H,
    8. Lee S,
    9. Yashiro M and
    10. Ohira M
    : Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer. BMC Cancer 20(1): 517, 2020. PMID: 32493247. DOI: 10.1186/s12885-020-07010-0
    OpenUrlCrossRefPubMed
    1. Lee JW,
    2. Sharma AR,
    3. Lee SS,
    4. Chun WJ and
    5. Kim HS
    : The C-reactive protein to albumin ratio predicts postoperative complication in patients who undergo gastrectomy for gastric cancer. Heliyon 6(6): e04220, 2020. PMID: 32577578. DOI: 10.1016/j.heliyon.2020.e04220
    OpenUrlCrossRefPubMed
    1. Yu Q,
    2. Li KZ,
    3. Fu YJ,
    4. Tang Y,
    5. Liang XQ,
    6. Liang ZQ and
    7. Bai JH
    : Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer. Ann Surg Treat Res 100(6): 338-346, 2021. PMID: 34136430. DOI: 10.4174/astr.2021.100.6.338
    OpenUrlCrossRefPubMed
    1. Aoyama T,
    2. Nakazono M,
    3. Segami K,
    4. Nagasawa S,
    5. Kano K,
    6. Yamada T,
    7. Maezawa Y,
    8. Hara K,
    9. Hashimoto I,
    10. Suematsu H,
    11. Watanabe H,
    12. Takahashi K,
    13. Numata M,
    14. Tamagawa H,
    15. Yukawa N,
    16. Rino Y,
    17. Ogata T and
    18. Oshima T
    : The clinical influence of the C-reactive protein-to-albumin ratio in patients who received curative treatment for gastric cancer. In Vivo 35(6): 3475-3482, 2021. PMID: 34697184. DOI: 10.21873/invivo.12648
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Liu Z,
    2. Chen L,
    3. Sun F,
    4. Lv B,
    5. Ge X,
    6. Shao L and
    7. Liu S
    : C-reactive protein/albumin ratio on the first day after surgery predicts short-term complications of gastrectomy for gastric cancer. Nutr Cancer 74(10): 3574-3581, 2022. PMID: 35762207. DOI: 10.1080/01635581.2022.2083190
    OpenUrlCrossRefPubMed
  44. ↵
    1. Yamanaka T,
    2. Matsumoto S,
    3. Teramukai S,
    4. Ishiwata R,
    5. Nagai Y and
    6. Fukushima M
    : The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73(3-4): 215-220, 2007. PMID: 18424885. DOI: 10.1159/000127412
    OpenUrlCrossRefPubMed
    1. Ubukata H,
    2. Motohashi G,
    3. Tabuchi T,
    4. Nagata H,
    5. Konishi S and
    6. Tabuchi T
    : Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102(7): 742-747, 2010. PMID: 20872813. DOI: 10.1002/jso.21725
    OpenUrlCrossRefPubMed
    1. Shimada H,
    2. Takiguchi N,
    3. Kainuma O,
    4. Soda H,
    5. Ikeda A,
    6. Cho A,
    7. Miyazaki A,
    8. Gunji H,
    9. Yamamoto H and
    10. Nagata M
    : High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13(3): 170-176, 2010. PMID: 20820986. DOI: 10.1007/s10120-010-0554-3
    OpenUrlCrossRefPubMed
    1. Jung MR,
    2. Park YK,
    3. Jeong O,
    4. Seon JW,
    5. Ryu SY,
    6. Kim DY and
    7. Kim YJ
    : Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 104(5): 504-510, 2011. PMID: 21618251. DOI: 10.1002/jso.21986
    OpenUrlCrossRefPubMed
  48. ↵
    1. Lee S,
    2. Oh SY,
    3. Kim SH,
    4. Lee JH,
    5. Kim MC,
    6. Kim KH and
    7. Kim HJ
    : Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 13: 350, 2013. PMID: 23876227. DOI: 10.1186/1471-2407-13-350
    OpenUrlCrossRefPubMed
    1. Cho IR,
    2. Park JC,
    3. Park CH,
    4. Jo JH,
    5. Lee HJ,
    6. Kim S,
    7. Shim CN,
    8. Lee H,
    9. Shin SK,
    10. Lee SK and
    11. Lee YC
    : Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 17(4): 703-710, 2014. PMID: 24442663. DOI: 10.1007/s10120-013-0330-2
    OpenUrlCrossRefPubMed
    1. Que Y,
    2. Qiu H,
    3. Li Y,
    4. Chen Y,
    5. Xiao W,
    6. Zhou Z and
    7. Zhang X
    : Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma. BMC Cancer 15: 648, 2015. PMID: 26432433. DOI: 10.1186/s12885-015-1654-6
    OpenUrlCrossRefPubMed
    1. el Aziz LM
    : Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Med Oncol 31(12): 311, 2014. PMID: 25367855. DOI: 10.1007/s12032-014-0311-2
    OpenUrlCrossRefPubMed
    1. Yuan D,
    2. Zhu K,
    3. Li K,
    4. Yan R,
    5. Jia Y and
    6. Dang C
    : The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction. J Surg Oncol 110(3): 333-340, 2014. PMID: 24889121. DOI: 10.1002/jso.23651
    OpenUrlCrossRefPubMed
    1. Hsu JT,
    2. Liao CK,
    3. Le PH,
    4. Chen TH,
    5. Lin CJ,
    6. Chen JS,
    7. Chiang KC and
    8. Yeh TS
    : Prognostic value of the preoperative neutrophil to lymphocyte ratio in resectable gastric cancer. Medicine (Baltimore) 94(39): e1589, 2015. PMID: 26426635. DOI: 10.1097/MD.0000000000001589
    OpenUrlCrossRefPubMed
    1. Kim JH,
    2. Han DS,
    3. Bang HY,
    4. Kim PS and
    5. Lee KY
    : Preoperative neutrophil-to-lymphocyte ratio is a prognostic factor for overall survival in patients with gastric cancer. Ann Surg Treat Res 89(2): 81-86, 2015. PMID: 26236697. DOI: 10.4174/astr.2015.89.2.81
    OpenUrlCrossRefPubMed
    1. Yu L,
    2. Lv CY,
    3. Yuan AH,
    4. Chen W and
    5. Wu AW
    : Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer. World J Gastroenterol 21(20): 6280-6286, 2015. PMID: 26034363. DOI: 10.3748/wjg.v21.i20.6280
    OpenUrlCrossRefPubMed
    1. Graziosi L,
    2. Marino E,
    3. De Angelis V,
    4. Rebonato A,
    5. Cavazzoni E and
    6. Donini A
    : Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer. Am J Surg 209(2): 333-337, 2015. PMID: 25190544. DOI: 10.1016/j.amjsurg.2014.06.014
    OpenUrlCrossRefPubMed
    1. Namikawa T,
    2. Munekage E,
    3. Munekage M,
    4. Maeda H,
    5. Yatabe T,
    6. Kitagawa H,
    7. Kobayashi M and
    8. Hanazaki K
    : Evaluation of systemic inflammatory response biomarkers in patients receiving chemotherapy for unresectable and recurrent advanced gastric cancer. Oncology 90(6): 321-326, 2016. PMID: 27225990. DOI: 10.1159/000446373
    OpenUrlCrossRefPubMed
    1. Ock CY,
    2. Nam AR,
    3. Lee J,
    4. Bang JH,
    5. Lee KH,
    6. Han SW,
    7. Kim TY,
    8. Im SA,
    9. Kim TY,
    10. Bang YJ and
    11. Oh DY
    : Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer 20(2): 254-262, 2017. PMID: 27147244. DOI: 10.1007/s10120-016-0613-5
    OpenUrlCrossRefPubMed
    1. Grenader T,
    2. Waddell T,
    3. Peckitt C,
    4. Oates J,
    5. Starling N,
    6. Cunningham D and
    7. Bridgewater J
    : Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol 27(4): 687-692, 2016. PMID: 26787231. DOI: 10.1093/annonc/mdw012
    OpenUrlCrossRefPubMed
    1. Mohri Y,
    2. Tanaka K,
    3. Toiyama Y,
    4. Ohi M,
    5. Yasuda H,
    6. Inoue Y and
    7. Kusunoki M
    : Impact of preoperative neutrophil to lymphocyte ratio and postoperative infectious complications on survival after curative gastrectomy for gastric cancer: a single institutional cohort study. Medicine (Baltimore) 95(11): e3125, 2016. PMID: 26986164. DOI: 10.1097/MD.0000000000003125
    OpenUrlCrossRefPubMed
    1. Wang SC,
    2. Chou JF,
    3. Strong VE,
    4. Brennan MF,
    5. Capanu M and
    6. Coit DG
    : Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg 263(2): 292-297, 2016. PMID: 25915915. DOI: 10.1097/SLA.0000000000001189
    OpenUrlCrossRefPubMed
    1. Fanotto V,
    2. Cordio S,
    3. Pasquini G,
    4. Fontanella C,
    5. Rimassa L,
    6. Leone F,
    7. Rosati G,
    8. Santini D,
    9. Giampieri R,
    10. Di Donato S,
    11. Tomasello G,
    12. Silvestris N,
    13. Pietrantonio F,
    14. Battaglin F,
    15. Avallone A,
    16. Scartozzi M,
    17. Lutrino ES,
    18. Melisi D,
    19. Antonuzzo L,
    20. Pellegrino A,
    21. Torri V and
    22. Aprile G
    : Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer 20(5): 825-833, 2017. PMID: 28028664. DOI: 10.1007/s10120-016-0681-6
    OpenUrlCrossRefPubMed
    1. Lieto E,
    2. Galizia G,
    3. Auricchio A,
    4. Cardella F,
    5. Mabilia A,
    6. Basile N,
    7. Del Sorbo G,
    8. Castellano P,
    9. Romano C,
    10. Orditura M and
    11. Napolitano V
    : Preoperative neutrophil to lymphocyte ratio and lymphocyte to monocyte ratio are prognostic factors in gastric cancers undergoing surgery. J Gastrointest Surg 21(11): 1764-1774, 2017. PMID: 28752404. DOI: 10.1007/s11605-017-3515-x
    OpenUrlCrossRefPubMed
    1. Qu J,
    2. Qu X,
    3. Li Z,
    4. Zhang J,
    5. Teng Y,
    6. Jin B,
    7. Zhao M,
    8. Yu P,
    9. Wang Z and
    10. Liu Y
    : Role of patient-, tumor- and systemic inflammatory response-related factors in predicting survival of patients with node-negative gastric cancer. Tumour Biol 39(6): 1010428317698374, 2017. PMID: 28618960. DOI: 10.1177/1010428317698374
    OpenUrlCrossRefPubMed
    1. Jin H,
    2. Sun J,
    3. Zhu K,
    4. Liu X,
    5. Zhang Q,
    6. Shen Q,
    7. Gao Y and
    8. Yu J
    : The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up. Onco Targets Ther 10: 2655-2664, 2017. PMID: 28579803. DOI: 10.2147/OTT.S135641
    OpenUrlCrossRefPubMed
    1. Ogata T,
    2. Satake H,
    3. Ogata M,
    4. Hatachi Y,
    5. Inoue K,
    6. Hamada M and
    7. Yasui H
    : Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget 9(77): 34520-34527, 2018. PMID: 30349646. DOI: 10.18632/oncotarget.26145
    OpenUrlCrossRefPubMed
    1. Kim H,
    2. Ro SM,
    3. Yang JH,
    4. Jeong JW,
    5. Lee JE,
    6. Roh SY and
    7. Kim IH
    : The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer. Korean J Intern Med 33(5): 990-999, 2018. PMID: 29722249. DOI: 10.3904/kjim.2016.293
    OpenUrlCrossRefPubMed
    1. Hwang GY,
    2. Baek DW,
    3. Cho HJ,
    4. Lee SJ,
    5. Chae YS,
    6. Kang BW,
    7. Lee IH,
    8. Kim JG,
    9. Seo AN,
    10. Bae HI,
    11. Park KB,
    12. Park JY,
    13. Kwon OK,
    14. Lee SS and
    15. Chung HY
    : Elevated neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with trastuzumab combination chemotherapy. Anticancer Res 38(5): 3151-3156, 2018. PMID: 29715156. DOI: 10.21873/anticanres.12578
    OpenUrlAbstract/FREE Full Text
    1. Jung M,
    2. Ryu MH,
    3. Oh DY,
    4. Kang M,
    5. Zang DY,
    6. Hwang IG,
    7. Lee KW,
    8. Kim KH,
    9. Shim BY,
    10. Song EK,
    11. Sym SJ,
    12. Han HS,
    13. Park YL,
    14. Kim JS,
    15. Lee HW,
    16. Lee MH,
    17. Koo DH,
    18. Song HS,
    19. Lee N,
    20. Yang SH,
    21. Choi DR,
    22. Hong YS,
    23. Lee KE,
    24. Maeng CH,
    25. Baek JH,
    26. Kim S,
    27. Kim YH,
    28. Rha SY,
    29. Cho JY and
    30. Kang YK
    : Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21(5): 819-830, 2018. PMID: 29427038. DOI: 10.1007/s10120-018-0806-1
    OpenUrlCrossRefPubMed
    1. Gonda K,
    2. Shibata M,
    3. Sato Y,
    4. Washio M,
    5. Takeshita H,
    6. Shigeta H,
    7. Ogura M,
    8. Oka S and
    9. Sakuramoto S
    : Elevated neutrophil-to-lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer. Mol Clin Oncol 7(6): 1073-1078, 2017. PMID: 29285377. DOI: 10.3892/mco.2017.1438
    OpenUrlCrossRefPubMed
    1. Mori M,
    2. Shuto K,
    3. Kosugi C,
    4. Narushima K,
    5. Hayashi H,
    6. Matsubara H and
    7. Koda K
    : An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer 18(1): 1261, 2018. PMID: 30558575. DOI: 10.1186/s12885-018-5171-2
    OpenUrlCrossRefPubMed
    1. Ramos-Esquivel A,
    2. Cordero-García E,
    3. Brenes-Redondo D and
    4. Alpízar-Alpízar W
    : The neutrophil-lymphocyte ratio is an independent prognostic factor for overall survival in hispanic patients with gastric adenocarcinoma. J Gastrointest Cancer, 2018. PMID: 30003495. DOI: 10.1007/s12029-018-0134-z
    OpenUrlCrossRefPubMed
    1. Zhang LX,
    2. Wei ZJ,
    3. Xu AM and
    4. Zang JH
    : Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study. Int J Surg 56: 320-327, 2018. PMID: 29969732. DOI: 10.1016/j.ijsu.2018.06.037
    OpenUrlCrossRefPubMed
    1. Zhang Y,
    2. Lu JJ,
    3. Du YP,
    4. Feng CX,
    5. Wang LQ and
    6. Chen MB
    : Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine (Baltimore) 97(12): e0144, 2018. PMID: 29561419. DOI: 10.1097/MD.0000000000010144
    OpenUrlCrossRefPubMed
    1. Szor DJ,
    2. Roncon Dias A,
    3. Pereira MA,
    4. Ramos MFKP,
    5. Zilberstein B,
    6. Cecconello I and
    7. Ribeiro U Jr.
    : Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer. J Surg Oncol 117(5): 851-857, 2018. PMID: 29509963. DOI: 10.1002/jso.25036
    OpenUrlCrossRefPubMed
    1. Miyamoto R,
    2. Inagawa S,
    3. Sano N,
    4. Tadano S,
    5. Adachi S and
    6. Yamamoto M
    : The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. Eur J Surg Oncol 44(5): 607-612, 2018. PMID: 29478743. DOI: 10.1016/j.ejso.2018.02.003
    OpenUrlCrossRefPubMed
  77. ↵
    1. Migita K,
    2. Matsumoto S,
    3. Wakatsuki K,
    4. Ito M,
    5. Kunishige T,
    6. Nakade H,
    7. Kitano M,
    8. Nakatani M and
    9. Sho M
    : The prognostic significance of inflammation-based markers in patients with recurrent gastric cancer. Surg Today 48(3): 282-291, 2018. PMID: 28836056. DOI: 10.1007/s00595-017-1582-y
    OpenUrlCrossRefPubMed
    1. Zhou D,
    2. Wu Y,
    3. Zhu Y,
    4. Lin Z,
    5. Yu D and
    6. Zhang T
    : The prognostic value of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in metastatic gastric cancer treated with systemic chemotherapy. J Cancer 11(14): 4205-4212, 2020. PMID: 32368303. DOI: 10.7150/jca.39575
    OpenUrlCrossRefPubMed
    1. Murakami Y,
    2. Saito H,
    3. Shimizu S,
    4. Kono Y,
    5. Shishido Y,
    6. Miyatani K,
    7. Matsunaga T,
    8. Fukumoto Y and
    9. Fujiwara Y
    : Neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with unresectable gastric cancer. Anticancer Res 39(5): 2583-2589, 2019. PMID: 31092456. DOI: 10.21873/anticanres.13381
    OpenUrlAbstract/FREE Full Text
    1. Inoue D,
    2. Sekiguchi S,
    3. Yamagata W,
    4. Maeda G,
    5. Yamada D,
    6. Fujiwara S,
    7. Itou S,
    8. Kurihara M,
    9. Hijioka Y,
    10. Shimoji K,
    11. Fujiki J,
    12. Nakazono A,
    13. Horike H,
    14. Yoshioka A,
    15. Ogura Y,
    16. Hatao F,
    17. Imamura K and
    18. Namiki S
    : Elevation of neutrophil-to-lymphocyte ratio before first-line chemotherapy predicts a poor prognosis for second-line chemotherapy in gastric cancer. Oncology 96(3): 140-146, 2019. PMID: 30368510. DOI: 10.1159/000493427
    OpenUrlCrossRefPubMed
    1. Tanaka H,
    2. Tamura T,
    3. Toyokawa T,
    4. Muguruma K,
    5. Miki Y,
    6. Kubo N,
    7. Sakurai K,
    8. Hirakawa K and
    9. Ohira M
    : Clinical relevance of postoperative neutrophil-lymphocyte ratio (NLR) to recurrence after adjuvant chemotherapy of S-1 for gastric cancer. Anticancer Res 38(6): 3745-3751, 2018. PMID: 29848737. DOI: 10.21873/anticanres.12655
    OpenUrlAbstract/FREE Full Text
    1. Kim HD,
    2. Ryu MH,
    3. Yoon S,
    4. Na YS,
    5. Moon M,
    6. Lee H,
    7. Song HG and
    8. Kang YK
    : Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel. Chin J Cancer Res 32(5): 621-630, 2020. PMID: 33223757. DOI: 10.21147/j.issn.1000-9604.2020.05.07
    OpenUrlCrossRefPubMed
    1. Zhao G,
    2. Liu N,
    3. Wang S,
    4. Guo J,
    5. Song X,
    6. Qi Y,
    7. Qiu W and
    8. Lv J
    : Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Medicine (Baltimore) 99(10): e19405, 2020. PMID: 32150090. DOI: 10.1097/MD.0000000000019405
    OpenUrlCrossRefPubMed
    1. Yong R and
    2. Meng Y
    : Preoperative neutrophil-lymphocyte ratio, an independent risk factor for postoperative cognitive dysfunction in elderly patients with gastric cancer. Geriatr Gerontol Int 20(10): 927-931, 2020. PMID: 32830911. DOI: 10.1111/ggi.14016
    OpenUrlCrossRefPubMed
    1. Li Z,
    2. Li S,
    3. Ying X,
    4. Zhang L,
    5. Shan F,
    6. Jia Y and
    7. Ji J
    : The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer 23(3): 540-549, 2020. PMID: 32072387. DOI: 10.1007/s10120-019-01027-6
    OpenUrlCrossRefPubMed
    1. Gou M,
    2. Qu T,
    3. Wang Z,
    4. Yan H,
    5. Si Y,
    6. Zhang Y and
    7. Dai G
    : Neutrophil-to-lymphocyte ratio (NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric cancer. J Immunol Res 2021: 2549295, 2021. PMID: 34993252. DOI: 10.1155/2021/2549295
    OpenUrlCrossRefPubMed
    1. Ruan DY,
    2. Chen YX,
    3. Wei XL,
    4. Wang YN,
    5. Wang ZX,
    6. Wu HX,
    7. Xu RH,
    8. Yuan SQ and
    9. Wang FH
    : Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterol Rep (Oxf) 9(6): 560-570, 2021. PMID: 34925853. DOI: 10.1093/gastro/goab032
    OpenUrlCrossRefPubMed
    1. Cousillas Castineiras A,
    2. Gallardo Martin E,
    3. Fernandez Montes A,
    4. Carmona Campos M,
    5. Covela Rua M,
    6. Salgado Fernandez M,
    7. Pellon Augusto ML,
    8. Martínez Lago N,
    9. Vidal Insua Y,
    10. Brozos Vazquez E,
    11. De La Camara J,
    12. Alonso Herrero A and
    13. Mendez Mendez JC
    : Dynamic perspective of the neutrophil-to-lymphocyte ratio in metastatic gastric cancer. J BUON 26(5): 2131-2140, 2021. PMID: 34761627.
    OpenUrlPubMed
    1. Park JH,
    2. Yeo JH,
    3. Kim YS,
    4. Park I,
    5. Ahn HK,
    6. Shin DB,
    7. Lee WK,
    8. Yang JY,
    9. Kim HS and
    10. Sym SJ
    : Predictive roles of HER2 gene amplification and neutrophil-to-lymphocyte ratio on survival in HER2-positive advanced gastric cancer treated with trastuzumab-based chemotherapy. Am J Clin Oncol 44(6): 232-238, 2021. PMID: 33710139. DOI: 10.1097/COC.0000000000000810
    OpenUrlCrossRefPubMed
    1. Yang S and
    2. Li S
    : Development of prognostic predictive model with neutrophil-lymphocyte ratio (NLR) in patients with gastric signet ring carcinoma. Medicine (Baltimore) 101(1): e28043, 2022. PMID: 35029873. DOI: 10.1097/MD.0000000000028043
    OpenUrlCrossRefPubMed
    1. Mori M,
    2. Shuto K,
    3. Hirano A,
    4. Narushima K,
    5. Kosugi C,
    6. Yamazaki M,
    7. Koda K and
    8. Yoshida M
    : Preoperative neutrophil-to-lymphocyte ratio may predict postoperative pneumonia in stage I-III gastric cancer patients after curative gastrectomy: a retrospective study. World J Surg 45(11): 3359-3369, 2021. PMID: 34333681. DOI: 10.1007/s00268-021-06264-4
    OpenUrlCrossRefPubMed
    1. Sato S,
    2. Kunisaki C,
    3. Takahashi M,
    4. Kubo H,
    5. Tsuchiya N,
    6. Sato K,
    7. Miyamoto H,
    8. Tamura Y,
    9. Kondo H,
    10. Tanaka Y,
    11. Kasahara K,
    12. Kosaka T,
    13. Akiyama H,
    14. Saigusa Y and
    15. Endo I
    : High postoperative neutrophil-lymphocyte ratio and low preoperative lymphocyte-monocyte ratio predict poor prognosis in gastric cancer patients receiving gastrectomy with positive lavage cytology: a retrospective cohort study. Langenbecks Arch Surg 406(7): 2295-2303, 2021. PMID: 34137915. DOI: 10.1007/s00423-021-02233-6
    OpenUrlCrossRefPubMed
    1. Yamakoshi Y,
    2. Tanaka H,
    3. Sakimura C,
    4. Mori T,
    5. Deguchi S,
    6. Yoshii M,
    7. Tamura T,
    8. Toyokawa T,
    9. Lee S,
    10. Muguruma K,
    11. Hirakawa K and
    12. Ohira M
    : Association between the preoperative neutrophil-to-lymphocyte ratio and tertiary lymphoid structures surrounding tumor in gastric cancer. Mol Clin Oncol 14(4): 76, 2021. PMID: 33680464. DOI: 10.3892/mco.2021.2238
    OpenUrlCrossRefPubMed
    1. Liu Z,
    2. Liang Y,
    3. Tang X and
    4. Qu H
    : Decrease in blood neutrophil-to-lymphocyte ratio indicates better survival after neoadjuvant chemotherapy in patients with advanced gastric cancer. Front Surg 8: 745748, 2021. PMID: 34869556. DOI: 10.3389/fsurg.2021.745748
    OpenUrlCrossRefPubMed
    1. Ishido K,
    2. Tanabe S,
    3. Katada C,
    4. Ishibashi Y,
    5. Kitahara G,
    6. Onoue M,
    7. Kubota Y,
    8. Furue Y,
    9. Wada T,
    10. Watanabe A and
    11. Kusano C
    : Evaluation of prognostic factors for unresectable or recurrent gastric cancer treated with nivolumab. J Gastrointest Cancer, 2022. PMID: 35437632. DOI: 10.1007/s12029-022-00823-1
    OpenUrlCrossRefPubMed
    1. Namikawa T,
    2. Shimizu S,
    3. Yokota K,
    4. Tanioka N,
    5. Munekage M,
    6. Uemura S,
    7. Maeda H,
    8. Kitagawa H,
    9. Kobayashi M and
    10. Hanazaki K
    : Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer. Langenbecks Arch Surg 407(2): 609-621, 2022. PMID: 34652563. DOI: 10.1007/s00423-021-02356-w
    OpenUrlCrossRefPubMed
  97. ↵
    1. Tur-Martínez J,
    2. Osorio J,
    3. Pérez-Romero N,
    4. Puértolas-Rico N,
    5. Pera M,
    6. Delgado S and
    7. Rodríguez-Santiago J
    : Preoperative neutrophil-to-lymphocyte ratio behaves as an independent prognostic factor even in patients with postoperative complications after curative resection for gastric cancer. Langenbecks Arch Surg 407(3): 1017-1026, 2022. PMID: 34999967. DOI: 10.1007/s00423-022-02432-9
    OpenUrlCrossRefPubMed
  98. ↵
    1. Messager M,
    2. Neofytou K,
    3. Chaudry MA and
    4. Allum WH
    : Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients. Eur J Surg Oncol 41(10): 1316-1323, 2015. PMID: 26166786. DOI: 10.1016/j.ejso.2015.06.007
    OpenUrlCrossRefPubMed
    1. Inaoka K,
    2. Kanda M,
    3. Uda H,
    4. Tanaka Y,
    5. Tanaka C,
    6. Kobayashi D,
    7. Takami H,
    8. Iwata N,
    9. Hayashi M,
    10. Niwa Y,
    11. Yamada S,
    12. Fujii T,
    13. Sugimoto H,
    14. Murotani K,
    15. Fujiwara M and
    16. Kodera Y
    : Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. World J Gastroenterol 23(14): 2519-2526, 2017. PMID: 28465636. DOI: 10.3748/wjg.v23.i14.2519
    OpenUrlCrossRefPubMed
  100. ↵
    1. Chen L,
    2. Hao Y,
    3. Cong X,
    4. Zou M,
    5. Li S,
    6. Zhu L,
    7. Song H and
    8. Xue Y
    : Peripheral venous blood platelet-to-lymphocyte ratio (PLR) for predicting the survival of patients with gastric cancer treated with SOX or XELOX regimen neoadjuvant chemotherapy. Technol Cancer Res Treat 18: 1533033819829485, 2019. PMID: 30760114. DOI: 10.1177/1533033819829485
    OpenUrlCrossRefPubMed
  101. ↵
    1. Watanabe M,
    2. Iwatsuki M,
    3. Iwagami S,
    4. Ishimoto T,
    5. Baba Y and
    6. Baba H
    : Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg 36(7): 1632-1639, 2012. PMID: 22407085. DOI: 10.1007/s00268-012-1526-z
    OpenUrlCrossRefPubMed
    1. Jiang N,
    2. Deng JY,
    3. Ding XW,
    4. Ke B,
    5. Liu N,
    6. Zhang RP and
    7. Liang H
    : Prognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancer. World J Gastroenterol 20(30): 10537-10544, 2014. PMID: 25132773. DOI: 10.3748/wjg.v20.i30.10537
    OpenUrlCrossRefPubMed
    1. Sun KY,
    2. Xu JB,
    3. Chen SL,
    4. Yuan YJ,
    5. Wu H,
    6. Peng JJ,
    7. Chen CQ,
    8. Guo P,
    9. Hao YT and
    10. He YL
    : Novel immunological and nutritional-based prognostic index for gastric cancer. World J Gastroenterol 21(19): 5961-5971, 2015. PMID: 26019461. DOI: 10.3748/wjg.v21.i19.5961
    OpenUrlCrossRefPubMed
    1. Lee JY,
    2. Kim HI,
    3. Kim YN,
    4. Hong JH,
    5. Alshomimi S,
    6. An JY,
    7. Cheong JH,
    8. Hyung WJ,
    9. Noh SH and
    10. Kim CB
    : Clinical significance of the prognostic nutritional index for predicting short- and long-term surgical outcomes after gastrectomy: a retrospective analysis of 7781 gastric cancer patients. Medicine (Baltimore) 95(18): e3539, 2016. PMID: 27149460. DOI: 10.1097/MD.0000000000003539
    OpenUrlCrossRefPubMed
    1. Hirahara N,
    2. Tajima Y,
    3. Fujii Y,
    4. Kaji S,
    5. Yamamoto T,
    6. Hyakudomi R,
    7. Taniura T and
    8. Kawabata Y
    : Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis. BMC Cancer 18(1): 285, 2018. PMID: 29534689. DOI: 10.1186/s12885-018-4201-4
    OpenUrlCrossRefPubMed
    1. Wang HX,
    2. Wang CC,
    3. Yang W,
    4. Gao LL and
    5. Yu SQ
    : Prognostic value of preoperative prognostic nutritional index in stage III gastric cancer after curative resection: a retrospective cohort study. Asia Pac J Clin Nutr 27(3): 540-545, 2018. PMID: 29737800. DOI: 10.6133/apjcn.072017.03
    OpenUrlCrossRefPubMed
    1. Luo Z,
    2. Zhou L,
    3. Balde AI,
    4. Li Z,
    5. He L,
    6. ZhenWei C,
    7. Zou Z,
    8. Huang S,
    9. Han S,
    10. Wei Zhou M,
    11. Zhang GQ and
    12. Cai Z
    : Prognostic impact of preoperative prognostic nutritional index in resected advanced gastric cancer: A multicenter propensity score analysis. Eur J Surg Oncol 45(3): 425-431, 2019. PMID: 30366877. DOI: 10.1016/j.ejso.2018.09.004
    OpenUrlCrossRefPubMed
    1. Park SH,
    2. Lee S,
    3. Song JH,
    4. Choi S,
    5. Cho M,
    6. Kwon IG,
    7. Son T,
    8. Kim HI,
    9. Cheong JH,
    10. Hyung WJ,
    11. Choi SH,
    12. Noh SH and
    13. Choi YY
    : Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. Eur J Surg Oncol 46(4 Pt A): 620-625, 2020. PMID: 31668977. DOI: 10.1016/j.ejso.2019.10.024
    OpenUrlCrossRefPubMed
    1. Zhang Y,
    2. Zhu JY,
    3. Zhou LN,
    4. Tang M,
    5. Chen MB and
    6. Tao M
    : Predicting the prognosis of gastric cancer by albumin/globulin ratio and the prognostic nutritional index. Nutr Cancer 72(4): 635-644, 2020. PMID: 31423840. DOI: 10.1080/01635581.2019.1651347
    OpenUrlCrossRefPubMed
    1. Xishan Z,
    2. Ye Z,
    3. Feiyan M,
    4. Liang X and
    5. Shikai W
    : The role of prognostic nutritional index for clinical outcomes of gastric cancer after total gastrectomy. Sci Rep 10(1): 17373, 2020. PMID: 33060715. DOI: 10.1038/s41598-020-74525-8
    OpenUrlCrossRefPubMed
    1. Xiao H,
    2. Zhou H,
    3. Zhang P,
    4. Xiao H,
    5. Liu K,
    6. Chen X,
    7. Quan H,
    8. Yin B,
    9. Li R,
    10. Huang G,
    11. Yin X and
    12. Ouyang Y
    : Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer. Eur J Clin Nutr 74(4): 555-564, 2020. PMID: 31548596. DOI: 10.1038/s41430-019-0502-1
    OpenUrlCrossRefPubMed
  112. ↵
    1. Sugawara K,
    2. Aikou S,
    3. Yajima S,
    4. Uemura Y,
    5. Okumura Y,
    6. Nishida M,
    7. Yagi K,
    8. Yamashita H and
    9. Seto Y
    : Pre- and post-operative low prognostic nutritional index influences survival in older patients with gastric carcinoma. J Geriatr Oncol 11(6): 989-996, 2020. PMID: 32146093. DOI: 10.1016/j.jgo.2020.02.007
    OpenUrlCrossRefPubMed
    1. Takechi H,
    2. Fujikuni N,
    3. Tanabe K,
    4. Hattori M,
    5. Amano H,
    6. Noriyuki T and
    7. Nakahara M
    : Using the preoperative prognostic nutritional index as a predictive factor for non-cancer-related death in post-curative resection gastric cancer patients: a retrospective cohort study. BMC Gastroenterol 20(1): 256, 2020. PMID: 32758144. DOI: 10.1186/s12876-020-01402-z
    OpenUrlCrossRefPubMed
    1. Takahashi T,
    2. Kaneoka Y,
    3. Maeda A,
    4. Takayama Y,
    5. Fukami Y and
    6. Uji M
    : The preoperative prognostic nutrition index is a prognostic indicator for survival in elderly gastric cancer patients after gastrectomy: a propensity score-matched analysis. Updates Surg 72(2): 483-491, 2020. PMID: 32193765. DOI: 10.1007/s13304-020-00745-2
    OpenUrlCrossRefPubMed
    1. Sasahara M,
    2. Kanda M,
    3. Ito S,
    4. Mochizuki Y,
    5. Teramoto H,
    6. Ishigure K,
    7. Murai T,
    8. Asada T,
    9. Ishiyama A,
    10. Matsushita H,
    11. Tanaka C,
    12. Kobayashi D,
    13. Fujiwara M,
    14. Murotani K and
    15. Kodera Y
    : The preoperative prognostic nutritional index predicts short-term and long-term outcomes of patients with stage II/III gastric cancer: analysis of a multi-institution dataset. Dig Surg 37(2): 135-144, 2020. PMID: 30840952. DOI: 10.1159/000497454
    OpenUrlCrossRefPubMed
    1. Watanabe H,
    2. Yamada T,
    3. Komori K,
    4. Hara K,
    5. Kano K,
    6. Takahashi K,
    7. Kumazu Y,
    8. Fujikawa H,
    9. Numata M,
    10. Aoyama T,
    11. Tamagawa H,
    12. Inokuchi Y,
    13. Machida N,
    14. Shiozawa M,
    15. Yukawa N,
    16. Morinaga S,
    17. Rino Y,
    18. Masuda M,
    19. Ogata T and
    20. Oshima T
    : Effect of Prognostic Nutrition Index in gastric or gastro-oesophageal junction cancer patients undergoing nivolumab monotherapy. In Vivo 35(1): 563-569, 2021. PMID: 33402510. DOI: 10.21873/invivo.12292
    OpenUrlAbstract/FREE Full Text
    1. Sánchez Y,
    2. Vaca-Paniagua F,
    3. Herrera L,
    4. Oñate L,
    5. Herrera-Goepfert R,
    6. Navarro-Martínez G,
    7. Cerrato D,
    8. Díaz-Velázquez C,
    9. Quezada EM,
    10. García-Cuellar C and
    11. Prada D
    : Nutritional indexes as predictors of survival and their genomic implications in gastric cancer patients. Nutr Cancer 73(8): 1429-1439, 2021. PMID: 32715775. DOI: 10.1080/01635581.2020.1797833
    OpenUrlCrossRefPubMed
    1. Demirelli B,
    2. Babacan NA,
    3. Ercelep Ö,
    4. Öztürk MA,
    5. Kaya S,
    6. Tanrıkulu E,
    7. Khalil S,
    8. Hasanov R,
    9. Alan Ö,
    10. Telli TA,
    11. Koca S,
    12. Arıbal ME,
    13. Kuzan B,
    14. Dane F and
    15. Yumuk PF
    : Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score predicts survival better than sarcopenia, cachexia and some inflammatory indices in metastatic gastric cancer. Nutr Cancer 73(2): 230-238, 2021. PMID: 32270713. DOI: 10.1080/01635581.2020.1749290
    OpenUrlCrossRefPubMed
    1. Zhang X,
    2. Fang H,
    3. Zeng Z,
    4. Zhang K,
    5. Lin Z,
    6. Deng G,
    7. Deng W,
    8. Guan L,
    9. Wei X,
    10. Li X,
    11. Jiang L and
    12. Xu L
    : Preoperative prognostic nutrition index as a prognostic indicator of survival in elderly patients undergoing gastric cancer surgery. Cancer Manag Res 13: 5263-5273, 2021. PMID: 34239325. DOI: 10.2147/CMAR.S316437
    OpenUrlCrossRefPubMed
    1. Liu JY,
    2. Dong HM,
    3. Wang WL,
    4. Wang G,
    5. Pan H,
    6. Chen WW,
    7. Wang Q and
    8. Wang ZJ
    : The effect of the prognostic nutritional index on the toxic side effects of radiochemotherapy and prognosis after radical surgery for gastric cancer. Cancer Manag Res 13: 3385-3392, 2021. PMID: 33889027. DOI: 10.2147/CMAR.S301140
    OpenUrlCrossRefPubMed
    1. Okubo K,
    2. Arigami T,
    3. Matsushita D,
    4. Tanaka T,
    5. Tsuruda Y,
    6. Noda M,
    7. Sasaki K,
    8. Mori S,
    9. Kurahara H and
    10. Ohtsuka T
    : Clinical impact of the prognostic nutritional index as a predictor of outcomes in patients with stage II/III gastric cancer: a retrospective cohort study. Oncology 99(6): 380-388, 2021. PMID: 33677434. DOI: 10.1159/000514572
    OpenUrlCrossRefPubMed
    1. Lee J,
    2. Choi SH,
    3. Baek JH,
    4. Baek DW,
    5. Kim JG and
    6. Kang BW
    : Clinical impact of prognostic nutrition index for advanced gastric cancer patients with peritoneal metastases treated nivolumab monotherapy. Chonnam Med J 58(1): 24-28, 2022. PMID: 35169556. DOI: 10.4068/cmj.2022.58.1.24
    OpenUrlCrossRefPubMed
    1. Konishi T,
    2. Kosuga T,
    3. Inoue H,
    4. Konishi H,
    5. Shiozaki A,
    6. Kubota T,
    7. Okamoto K,
    8. Fujiwara H and
    9. Otsuji E
    : Significance of preoperative prognostic nutritional index in the perioperative management of gastric cancer. J Gastrointest Surg 26(3): 558-569, 2022. PMID: 34725783. DOI: 10.1007/s11605-021-05168-x
    OpenUrlCrossRefPubMed
  124. ↵
    1. Xu Z,
    2. Chen X,
    3. Yuan J,
    4. Wang C,
    5. An J and
    6. Ma X
    : Correlations of preoperative systematic immuno-inflammatory index and prognostic nutrition index with a prognosis of patients after radical gastric cancer surgery. Surgery 172(1): 150-159, 2022. PMID: 35168816. DOI: 10.1016/j.surg.2022.01.006
    OpenUrlCrossRefPubMed
  125. ↵
    1. Ryo S,
    2. Kanda M,
    3. Ito S,
    4. Mochizuki Y,
    5. Teramoto H,
    6. Ishigure K,
    7. Murai T,
    8. Asada T,
    9. Ishiyama A,
    10. Matsushita H,
    11. Tanaka C,
    12. Kobayashi D,
    13. Fujiwara M,
    14. Murotani K and
    15. Kodera Y
    : The controlling nutritional status score serves as a predictor of short- and long-term outcomes for patients with stage 2 or 3 gastric cancer: analysis of a multi-institutional data set. Ann Surg Oncol 26(2): 456-464, 2019. PMID: 30565044. DOI: 10.1245/s10434-018-07121-w
    OpenUrlCrossRefPubMed
    1. Liu X,
    2. Zhang D,
    3. Lin E,
    4. Chen Y,
    5. Li W,
    6. Chen Y,
    7. Sun X and
    8. Zhou Z
    : Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer. BMC Cancer 18(1): 699, 2018. PMID: 29954375. DOI: 10.1186/s12885-018-4616-y
    OpenUrlCrossRefPubMed
    1. Kuroda D,
    2. Sawayama H,
    3. Kurashige J,
    4. Iwatsuki M,
    5. Eto T,
    6. Tokunaga R,
    7. Kitano Y,
    8. Yamamura K,
    9. Ouchi M,
    10. Nakamura K,
    11. Baba Y,
    12. Sakamoto Y,
    13. Yamashita Y,
    14. Yoshida N,
    15. Chikamoto A and
    16. Baba H
    : Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer 21(2): 204-212, 2018. PMID: 28656485. DOI: 10.1007/s10120-017-0744-3
    OpenUrlCrossRefPubMed
    1. Huang Y,
    2. Huang Y,
    3. Lu M,
    4. Sun W,
    5. Sun X,
    6. Chen X,
    7. Li L,
    8. Chandoo A and
    9. Li L
    : Controlling Nutritional Status (CONUT) score is a predictor of post-operative outcomes in elderly gastric cancer patients undergoing curative gastrectomy: a prospective study. Cancer Manag Res 11: 9793-9800, 2019. PMID: 31819617. DOI: 10.2147/CMAR.S233872
    OpenUrlCrossRefPubMed
    1. Hirahara N,
    2. Tajima Y,
    3. Fujii Y,
    4. Kaji S,
    5. Kawabata Y,
    6. Hyakudomi R,
    7. Yamamoto T and
    8. Taniura T
    : Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis. Surg Endosc 33(12): 4143-4152, 2019. PMID: 30838449. DOI: 10.1007/s00464-019-06723-z
    OpenUrlCrossRefPubMed
    1. Suzuki S,
    2. Kanaji S,
    3. Yamamoto M,
    4. Oshikiri T,
    5. Nakamura T and
    6. Kakeji Y
    : Controlling Nutritional Status (CONUT) score predicts outcomes of curative resection for gastric cancer in the elderly. World J Surg 43(4): 1076-1084, 2019. PMID: 30569221. DOI: 10.1007/s00268-018-04889-6
    OpenUrlCrossRefPubMed
    1. Jin H,
    2. Zhu K and
    3. Wang W
    : The predictive values of pretreatment controlling nutritional status (CONUT) score in estimating short- and long-term outcomes for patients with gastric cancer treated with neoadjuvant chemotherapy and curative gastrectomy. J Gastric Cancer 21(2): 155-168, 2021. PMID: 34234977. DOI: 10.5230/jgc.2021.21.e14
    OpenUrlCrossRefPubMed
    1. Zhu X,
    2. Zhao Y,
    3. Ma F and
    4. Wu S
    : Controlling Nutritional Status score predict the individualized survival of patients with gastric cancer. Asia Pac J Clin Nutr 30(1): 51-59, 2021. PMID: 33787040. DOI: 10.6133/apjcn.202103_30(1).0007
    OpenUrlCrossRefPubMed
    1. Sun F,
    2. Zhang C,
    3. Liu Z,
    4. Ai S,
    5. Guan W and
    6. Liu S
    : Controlling Nutritional Status (CONUT) score as a predictive marker for short-term complications following gastrectomy of gastric cancer: a retrospective study. BMC Gastroenterol 21(1): 107, 2021. PMID: 33663423. DOI: 10.1186/s12876-021-01682-z
    OpenUrlCrossRefPubMed
    1. Qian Y,
    2. Liu H,
    3. Pan J,
    4. Yu W,
    5. Lv J,
    6. Yan J,
    7. Gao J,
    8. Wang X,
    9. Ge X and
    10. Zhou W
    : Preoperative Controlling Nutritional Status (CONUT) score predicts short-term outcomes of patients with gastric cancer after laparoscopy-assisted radical gastrectomy. World J Surg Oncol 19(1): 25, 2021. PMID: 33485347. DOI: 10.1186/s12957-021-02132-6
    OpenUrlCrossRefPubMed
    1. Chen L,
    2. Sun H,
    3. Zhao R,
    4. Huang R,
    5. Pan H,
    6. Zuo Y,
    7. Zhang L,
    8. Xue Y,
    9. Li X and
    10. Song H
    : Controlling Nutritional Status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes. Front Pharmacol 13: 836958, 2022. PMID: 35308215. DOI: 10.3389/fphar.2022.836958
    OpenUrlCrossRefPubMed
    1. Aoyama T,
    2. Komori K,
    3. Nakazano M,
    4. Hara K,
    5. Tamagawa H,
    6. Kazama K,
    7. Hashimoto I,
    8. Yamada T,
    9. Maezawa Y,
    10. Segami K,
    11. Kano K,
    12. Nagasawa S,
    13. Yukawa N,
    14. Rino Y,
    15. Ogata T and
    16. Oshima T
    : The clinical influence of the CONUT score on survival of patients with gastric cancer receiving curative treatment. In Vivo 36(2): 942-948, 2022. PMID: 35241553. DOI: 10.21873/invivo.12784
    OpenUrlAbstract/FREE Full Text
  137. ↵
    1. Xiao Q,
    2. Li X,
    3. Duan B,
    4. Li X,
    5. Liu S,
    6. Xu B,
    7. Shi S,
    8. Zhang J,
    9. Qin H,
    10. Duan X and
    11. Pu Y
    : Clinical significance of controlling nutritional status score (CONUT) in evaluating outcome of postoperative patients with gastric cancer. Sci Rep 12(1): 93, 2022. PMID: 34997105. DOI: 10.1038/s41598-021-04128-4
    OpenUrlCrossRefPubMed
  138. ↵
    1. Liu J,
    2. Chen S,
    3. Geng Q,
    4. Liu X,
    5. Kong P,
    6. Zhan Y and
    7. Xu D
    : Prognostic value of pretreatment albumin-globulin ratio in predicting long-term mortality in gastric cancer patients who underwent D2 resection. Onco Targets Ther 10: 2155-2162, 2017. PMID: 28458559. DOI: 10.2147/OTT.S99282
    OpenUrlCrossRefPubMed
  139. ↵
    1. Cheng CB,
    2. Zhang QX,
    3. Zhuang LP and
    4. Sun JW
    : Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study. Jpn J Clin Oncol 50(10): 1141-1149, 2020. PMID: 32564084. DOI: 10.1093/jjco/hyaa099
    OpenUrlCrossRefPubMed
    1. Okugawa Y,
    2. Toiyama Y,
    3. Yamamoto A,
    4. Shigemori T,
    5. Ichikawa T,
    6. Yin C,
    7. Suzuki A,
    8. Fujikawa H,
    9. Yasuda H,
    10. Hiro J,
    11. Yoshiyama S,
    12. Ohi M,
    13. Araki T,
    14. McMillan DC and
    15. Kusunoki M
    : Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr 39(4): 1209-1217, 2020. PMID: 31155370. DOI: 10.1016/j.clnu.2019.05.009
    OpenUrlCrossRefPubMed
  141. ↵
    1. Aoyama T,
    2. Nakazano M,
    3. Nagasawa S,
    4. Hara K,
    5. Komori K,
    6. Tamagawa H,
    7. Maezawa Y,
    8. Segami K,
    9. Kano K,
    10. Ogata T,
    11. Yukawa N,
    12. Rino Y and
    13. Oshima T
    : The association of the lymphocyte-to-C-reactive-protein ratio with gastric cancer patients who receive curative treatment. In Vivo 36(1): 482-489, 2022. PMID: 34972752. DOI: 10.21873/invivo.12728
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Clinical Impact of Nutrition and Inflammation Assessment Tools in Gastric Cancer Treatment
TORU AOYAMA, KENTARO HARA, KEISUKE KAZAMA, YUKIO MAEZAWA
Anticancer Research Nov 2022, 42 (11) 5167-5180; DOI: 10.21873/anticanres.16023
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords